TY - JOUR
T1 - International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
AU - Rajkumar, S. Vincent
AU - Dimopoulos, Meletios A.
AU - Palumbo, Antonio
AU - Blade, Joan
AU - Merlini, Giampaolo
AU - Mateos, María Victoria
AU - Kumar, Shaji
AU - Hillengass, Jens
AU - Kastritis, Efstathios
AU - Richardson, Paul
AU - Landgren, Ola
AU - Paiva, Bruno
AU - Dispenzieri, Angela
AU - Weiss, Brendan
AU - LeLeu, Xavier
AU - Zweegman, Sonja
AU - Lonial, Sagar
AU - Rosinol, Laura
AU - Zamagni, Elena
AU - Jagannath, Sundar
AU - Sezer, Orhan
AU - Kristinsson, Sigurdur Y.
AU - Caers, Jo
AU - Usmani, Saad Z.
AU - Lahuerta, Juan José
AU - Johnsen, Hans Erik
AU - Beksac, Meral
AU - Cavo, Michele
AU - Goldschmidt, Hartmut
AU - Terpos, Evangelos
AU - Kyle, Robert A.
AU - Anderson, Kenneth C.
AU - Durie, Brian G.M.
AU - Miguel, Jesus F.San
N1 - Funding Information:
MAD reports personal fees from Celgene, Ortho Biotech, and Onyx. AP reports personal fees from Amgen, Bristol-Myers Squibb, Genmab A/S, Janssen-Cilag, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Celgene, Sanofi Aventis, and Array BioPharma. JB reports personal fees from Celgene and Janssen. GM reports personal fees from Millennium Takeda. SK reports grants from Celgene, Millennium, Novartis, Cephalon/Teva, Abbvie, and Onyx. PR has been a member of advisory committees for Millennium, Celgene, Johnson & Johnson, and Novartis. BP has received honoraria from Millennium, Celgene, Janssen, and The Binding Site Group Ltd. AD reports grants from Celgene, Millennium, Pfizer, and Jannsen. BW reports grants and personal fees from Janssen Research and Development, personal fees from Celgene and Onyx, and grants from Millennium. SZ reports grants from Celgene, Janssen, and Millennium. SL reports personal fees from Millennium, Celgene, Novartis, Onyx, Sanofi, Janssen, and Bristol-Myers Squibb. LR has received honoraria from Janssen and Celgene. EZ reports grants from Jansen-Cilag and Celgene. SJ has been a consultant for Celgene, Sanofi, and Bristol-Myers Squibb. OS reports personal fees from Celgene and Janssen. MB is in the speakers bureau for Celgene, Janssen-Cilag and Amgen, and serves on advisory boards for Janssen-Cilag, Bristol-Myers Squibb, and Novartis. MC reports personal fees from Janssen, Celgene, Millennium, Onyx, and Bristol-Myers Squibb. KCA reports personal fees from Celgene, Millennium, Gilead, Sanofi Aventis, and Onyx. All other authors declare no competing interests.
Publisher Copyright:
© 2014 Elsevier Ltd.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.
AB - This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.
UR - http://www.scopus.com/inward/record.url?scp=84908604358&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908604358&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(14)70442-5
DO - 10.1016/S1470-2045(14)70442-5
M3 - Review article
C2 - 25439696
AN - SCOPUS:84908604358
SN - 1470-2045
VL - 15
SP - e538-e548
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 12
ER -